Lördag 26 Oktober | 01:55:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-19 14:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-16 08:00 Kvartalsrapport 2025-Q2
2025-04-24 - Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-19 14:00 Bokslutskommuniké 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning BIOT 1.60 SEK
2024-04-25 - Kvartalsrapport 2024-Q1
2024-04-25 - Årsstämma
2024-02-15 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-28 - X-dag ordinarie utdelning BIOT 1.60 SEK
2023-04-27 - Kvartalsrapport 2023-Q1
2023-04-27 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning BIOT 1.55 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BIOT 1.50 SEK
2021-04-28 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning BIOT 0.00 SEK
2020-06-04 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-07 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-07-16 - Kvartalsrapport 2019-Q2
2019-04-25 - X-dag ordinarie utdelning BIOT 1.50 SEK
2019-04-24 - Kvartalsrapport 2019-Q1
2019-04-24 - Årsstämma
2019-02-07 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-07-16 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning BIOT 1.40 SEK
2018-04-26 - Kvartalsrapport 2018-Q1
2018-04-26 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-07-18 - Kvartalsrapport 2017-Q2
2017-04-28 - X-dag ordinarie utdelning BIOT 1.25 SEK
2017-04-27 - Årsstämma
2017-02-09 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - Kvartalsrapport 2016-Q2
2016-04-29 - X-dag ordinarie utdelning BIOT 1.00 SEK
2016-04-29 - X-dag bonusutdelning BIOT 0.25
2016-04-28 - Kvartalsrapport 2016-Q1
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-29 - X-dag ordinarie utdelning BIOT 0.75 SEK
2015-04-28 - Kvartalsrapport 2015-Q1
2015-04-28 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-10-30 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-04-29 - X-dag ordinarie utdelning BIOT 0.60 SEK
2014-04-28 - Kvartalsrapport 2014-Q1
2014-04-28 - Årsstämma
2014-02-13 - Bokslutskommuniké 2013
2013-10-25 - Kvartalsrapport 2013-Q3
2013-08-15 - Kvartalsrapport 2013-Q2
2013-04-26 - X-dag ordinarie utdelning BIOT 0.50 SEK
2013-04-25 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-12 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-17 - Kvartalsrapport 2012-Q2
2012-04-27 - X-dag ordinarie utdelning BIOT 0.40 SEK
2012-04-26 - Kvartalsrapport 2012-Q1
2012-04-26 - Årsstämma
2012-02-09 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-17 - Kvartalsrapport 2011-Q2
2011-04-28 - X-dag ordinarie utdelning BIOT 0.25 SEK
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-10 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-13 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning BIOT 0.20 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-11 - Bokslutskommuniké 2009
2009-10-27 - Kvartalsrapport 2009-Q3
2009-08-14 - Kvartalsrapport 2009-Q2
2009-04-28 - X-dag ordinarie utdelning BIOT 0.20 SEK
2009-04-27 - Kvartalsrapport 2009-Q1
2009-04-27 - Årsstämma

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Biotage är verksamt inom bioteknik. Bolaget tillhandahåller lösningar inom kromatografi, organisk syntes och provberedning. Bolaget har verksamhet på global nivå, främst koncentrerat till Europa, Nordamerika och Asien och en stor del av projekten bedrivs även i samarbete med övriga aktörer inom nämnd marknad. Kunderna återfinns inom vård och omsorg, samt inom livsmedelsindustrin.
2024-08-13 07:45:00

BiotageAB (STO:BIOT) (“Biotage”), the leading global separations Company developing intelligent workflow solutions for drug discovery and development through to diagnostics, has today announced the appointment of Frederic Vanderhaegen as Chief Executive Officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member.

Frederic Vanderhaegen is a prominent life science leader with 30+ years’ experience leading complex organisations with portfolios including laboratory products, diagnostics, and medical devices. He is ideally positioned to lead the company through its next ambitious phase of growth.

Commenting on the appointment, Kieran Murphy, Chair of the Board said:

“We are delighted to welcome Frederic Vanderhaegen as the new CEO of Biotage. He brings a wealth of experience and a proven track record of success to the role. We are confident that Frederic will drive a continued phase of growth and deliver significant value to our shareholders. The Board looks forward to supporting him in this exciting new chapter for the company.”

On behalf of the board, I would like to thank Torben for his outstanding leadership during this transitional period. His deep knowledge of the business and unwavering commitment to the company over the past almost twenty years, first as CEO and then as Chairman, has been exceptional.

Torben Jørgensen interim CEO and Board Member added:

“I have very much enjoyed working closely with the Biotage team since January and I am delighted with the progress we have made on many fronts. I am excited to have Frederic as the new CEO and am committed to ensuring a smooth handover”

Frederic Vanderhaegen, new CEO, commented:

“I am thrilled to take on the role of CEO at Biotage. This is an exciting time for the company, and I am confident that we can build on our strong foundations and deliver exceptional value to our shareholders, customers, and employees. I look forward to working closely with the talented team and board at Biotage to drive growth and innovation.”

Frederic joins Biotage from Avantor where he was General Manager and Executive Vice President for Europe. He also led the global portfolio for the life science business, sourcing and commercial excellence teams. Prior to Avantor, he worked for Ortho Clinical Diagnostics, Danaher, Tecan and Millipore in various senior leadership positions.

Frederic holds a Biochemical Engineering degree from Haute Ecole Lucia Debroeckere, a Chemical and Agricultural Engineering degree from Universite Libre de Bruxelles and an MBA from the Open University.